SEARCH

SEARCH BY CITATION

References

  • Azab, F., Vali, S., Abraham, J., Potter, N., Muz, B., de la Puente, P., Fiala, M., Paasch, J., Sultana, Z., Tyagi, A., Abbasi, T., Vij, R. & Azab, A.K. (2014) PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance. British Journal of Haematology, 165, 89101.
  • Barbieri, C.E., Barton, C.E. & Pietenpol, J.A. (2003) Delta Np63 alpha expression is regulated by the phosphoinositide 3-kinase pathway. Journal of Biological Chemistry, 278, 5140851414.
  • Bartholomeusz, C. & Gonzalez-Angulo, A.M. (2012) Targeting the PI3K signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets, 16, 121130.
  • Baumann, P., Mandl-Weber, S., Oduncu, F. & Schmidmaier, R. (2009) The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Experimental Cell Research, 315, 485497.
  • Brana, I. & Siu, L.L. (2012) Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment. BMC Medicine, 10, 161.
  • Bruhn, M.A., Pearson, R.B., Hannan, R.D. & Sheppard, K.E. (2013) AKT-independent PI3-K signaling in cancer – emerging role for SGK3. Cancer Management and Research, 5, 281292.
  • Chapman, M.A., Lawrence, M.S., Keats, J.J., Cibulskis, K., Sougnez, C., Schinzel, A.C., Harview, C.L., Brunet, J.P., Ahmann, G.J., Adli, M., Anderson, K.C., Ardlie, K.G., Auclair, D., Baker, A., Bergsagel, P.L., Bernstein, B.E., Drier, Y., Fonseca, R., Gabriel, S.B., Hofmeister, C.C., Jagannath, S., Jakubowiak, A.J., Krishnan, A., Levy, J., Liefeld, T., Lonial, S., Mahan, S., Mfuko, B., Monti, S., Perkins, L.M., Onofrio, R., Pugh, T.J., Rajkumar, S.V., Ramos, A.H., Siegel, D.S., Sivachenko, A., Stewart, A.K., Trudel, S., Vij, R., Voet, D., Winckler, W., Zimmerman, T., Carpten, J., Trent, J., Hahn, W.C., Garraway, L.A., Meyerson, M., Lander, E.S., Getz, G. & Golub, T.R. (2011) Initial genome sequencing and analysis of multiple myeloma. Nature, 471, 467472.
  • Chesi, M. & Bergsagel, P.L. (2011) Many multiple myelomas: making more of the molecular mayhem. Hematology/The Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2011, 344353.
  • Chou, T.C. (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological Reviews, 58, 621681.
  • Courtney, K.D., Corcoran, R.B. & Engelman, J.A. (2010) The PI3K pathway as drug target in human cancer. Journal of Clinical Oncology, 28, 10751083.
  • De, P., Dey, N., Terakedis, B., Bergsagel, P.L., Li, Z.H., Mahadevan, D., Garlich, J.R., Trudel, S., Makale, M.T. & Durden, D.L. (2013) An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo. Cancer Chemotherapy and Pharmacology, 71, 867881.
  • Downward, J. (2004) PI 3-kinase, Akt and cell survival. Seminars in Cell & Developmental Biology, 15, 177182.
  • Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J.W., Comber, H., Forman, D. & Bray, F. (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European Journal of Cancer, 49, 13741403.
  • Foukas, L.C., Berenjeno, I.M., Gray, A., Khwaja, A. & Vanhaesebroeck, B. (2010) Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proceedings of the National Academy of Sciences of the United States of America, 107, 1138111386.
  • Furet, P., Guagnano, V., Fairhurst, R.A., Imbach-Weese, P., Bruce, I., Knapp, M., Fritsch, C., Blasco, F., Blanz, J., Aichholz, R., Hamon, J., Fabbro, D. & Caravatti, G. (2013) Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorganic & Medicinal Chemistry Letters, 23, 37413748.
  • Glassford, J., Kassen, D., Quinn, J., Stengel, C., Kallinikou, K., Khwaja, A. & Yong, K.L. (2012) Inhibition of cell cycle progression by dual phosphatidylinositol-3-kinase and mTOR blockade in cyclin D2 positive multiple myeloma bearing IgH translocations. Blood Cancer J, 2, e50.
  • Guillermet-Guibert, J., Bjorklof, K., Salpekar, A., Gonella, C., Ramadani, F., Bilancio, A., Meek, S., Smith, A.J., Okkenhaug, K. & Vanhaesebroeck, B. (2008) The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proceedings of the National Academy of Sciences of the United States of America, 105, 82928297.
  • Hsu, J., Shi, Y., Krajewski, S., Renner, S., Fisher, M., Reed, J.C., Franke, T.F. & Lichtenstein, A. (2001) The AKT kinase is activated in multiple myeloma tumor cells. Blood, 98, 28532855.
  • Ikeda, H., Hideshima, T., Fulciniti, M., Perrone, G., Miura, N., Yasui, H., Okawa, Y., Kiziltepe, T., Santo, L., Vallet, S., Cristea, D., Calabrese, E., Gorgun, G., Raje, N.S., Richardson, P., Munshi, N.C., Lannutti, B.J., Puri, K.D., Giese, N.A. & Anderson, K.C. (2010) PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood, 116, 14601468.
  • Irarrazabal, C.E., Burg, M.B., Ward, S.G. & Ferraris, J.D. (2006) Phosphatidylinositol 3-kinase mediates activation of ATM by high NaCl and by ionizing radiation: role in osmoprotective transcriptional regulation. Proceedings of the National Academy of Sciences of the United States of America, 103, 88828887.
  • Ismail, S.I., Mahmoud, I.S., Msallam, M.M. & Sughayer, M.A. (2009) Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma. Leukemia Research, 34, 824826.
  • Kuehl, W.M. & Bergsagel, P.L. (2012) Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest, 122, 34563463.
  • Kumar, S.K., Dispenzieri, A., Lacy, M.Q., Gertz, M.A., Buadi, F.K., Pandey, S., Kapoor, P., Dingli, D., Hayman, S.R., Leung, N., Lust, J., McCurdy, A., Russell, S.J., Zeldenrust, S.R., Kyle, R.A. & Rajkumar, S.V. (2013) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia, doi: 10.1038/leu.2013.313.
  • Lannutti, B.J., Meadows, S.A., Herman, S.E., Kashishian, A., Steiner, B., Johnson, A.J., Byrd, J.C., Tyner, J.W., Loriaux, M.M., Deininger, M., Druker, B.J., Puri, K.D., Ulrich, R.G. & Giese, N.A. (2011) CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood, 117, 591594.
  • Leich, E., Weißbach, S., Klein, H.U., Grieb, T., Pischimarov, J., Stühmer, T., Chatterjee, M., Steinbrunn, T., Langer, C., Eilers, M., Knop, S., Einsele, H., Bargou, R. & Rosenwald, A. (2013) Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules. Blood Cancer J, 3, e102.
  • Leopoldt, D., Hanck, T., Exner, T., Maier, U., Wetzker, R. & Nürnberg, B. (1998) Gbetagamma stimulates phosphoinositide 3-kinase-gamma by direct interaction with two domains of the catalytic p110 subunit. Journal of Biological Chemistry, 273, 70247029.
  • Ludwig, H. & Sonneveld, P. (2012) Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy? Leukemia Research, 36, S27S34.
  • Maira, S.M., Pecchi, S., Huang, A., Burger, M., Knapp, M., Sterker, D., Schnell, C., Guthy, D., Nagel, T., Wiesmann, M., Brachmann, S., Fritsch, C., Dorsch, M., Chene, P., Shoemaker, K., De Pover, A., Menezes, D., Martiny-Baron, G., Fabbro, D., Wilson, C.J., Schlegel, R., Hofmann, F., Garcia-Echeverria, C., Sellers, W.R. & Voliva, C.F. (2012) Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Molecular Cancer Therapeutics, 11, 317328.
  • Markman, B., Tao, J.J. & Scaltriti, M. (2013) PI3K pathway inhibitors: better not left alone. Current Pharmaceutical Design, 19, 895906.
  • Martini, M., Ciraolo, E., Gulluni, F. & Hirsch, E. (2013) Targeting PI3K in cancer: any good news? Front Oncol, 3, 108.
  • Mendoza, M.C., Er, E.E. & Blenis, J. (2011) The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends in Biochemical Sciences, 36, 320328.
  • Morgan, G.J., Walker, B.A. & Davies, F.E. (2012) The genetic architecture of multiple myeloma. Nature Reviews Cancer, 12, 335348.
  • Müller, C.I., Miller, C.W., Hofmann, W.K., Gross, M.E., Walsh, C.S., Kawamata, N., Luong, Q.T. & Koeffler, H.P. (2007) Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene. Leukemia Research, 31, 2732.
  • Munugalavadla, V., Mariathasan, S., Slaga, D., Du, C., Berry, L., Del Rosario, G., Yan, Y., Boe, M., Sun, L., Friedman, L.S., Chesi, M., Leif Bergsagel, P. & Ebens, A. (2014) The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma. Oncogene, 33, 316325.
  • Pal, I. & Mandal, M. (2012) PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacologica Sinica, 33, 14411458.
  • Palumbo, A. & Anderson, K. (2011) Multiple myeloma. New England Journal of Medicine, 364, 10461060.
  • Palumbo, A., Bringhen, S., Ludwig, H., Dimopoulos, M.A., Blade, J., Mateos, M.V., Rosinol, L., Boccadoro, M., Cavo, M., Lokhorst, H., Zweegman, S., Terpos, E., Davies, F., Driessen, C., Gimsing, P., Gramatzki, M., Hajek, R., Johnsen, H.E., Leal Da Costa, F., Sezer, O., Spencer, A., Beksac, M., Morgan, G., Einsele, H., San Miguel, J.F. & Sonneveld, P. (2011) Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood, 118, 45194529.
  • Pene, F., Claessens, Y.E., Muller, O., Viguie, F., Mayeux, P., Dreyfus, F., Lacombe, C. & Bouscary, D. (2002) Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene, 21, 65876597.
  • Pollak, M. (2012) The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nature Reviews Cancer, 12, 159169.
  • Pomel, V., Klicic, J., Covini, D., Church, D.D., Shaw, J.P., Roulin, K., Burgat-Charvillon, F., Valognes, D., Camps, M., Chabert, C., Gillieron, C., Francon, B., Perrin, D., Leroy, D., Gretener, D., Nichols, A., Vitte, P.A., Carboni, S., Rommel, C., Schwarz, M.K. & Ruckle, T. (2006) Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. Journal of Medicinal Chemistry, 49, 38573871.
  • Ramakrishnan, V., Kimlinger, T., Haug, J., Painuly, U., Wellik, L., Halling, T., Rajkumar, S.V. & Kumar, S. (2012) Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway. PLoS ONE, 7, e50005.
  • Rodon, J., Dienstmann, R., Serra, V. & Tabernero, J. (2013) Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol, 10, 143153.
  • Samuels, Y. & Waldman, T. (2010) Oncogenic mutations of PIK3CA in human cancers. Current Topics in Microbiology and Immunology, 347, 2141.
  • Schmidt, E.E., Pelz, O., Buhlmann, S., Kerr, G., Horn, T. & Boutros, M. (2013) GenomeRNAi: a database for cell-based and in vivo RNAi phenotypes, 2013 update. Nucleic Acids Research, 41, D1021D1026.
  • She, Q.B., Halilovic, E., Ye, Q., Zhen, W., Shirasawa, S., Sasazuki, T., Solit, D.B. & Rosen, N. (2010) 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell, 18, 3951.
  • Siegel, R., Naishadham, D. & Jemal, A. (2013) Cancer statistics, 2013. CA: A Cancer Journal for Clinicians, 63, 1130.
  • Steinbrunn, T., Stühmer, T., Gattenlöhner, S., Rosenwald, A., Mottok, A., Unzicker, C., Einsele, H., Chatterjee, M. & Bargou, R.C. (2011) Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival. Blood, 117, 19982004.
  • Steinbrunn, T., Stühmer, T., Sayehli, C., Chatterjee, M., Einsele, H. & Bargou, R.C. (2012) Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma. British Journal of Haematology, 159, 430440.
  • Stengel, C., Cheung, C.W., Quinn, J., Yong, K. & Khwaja, A. (2012) Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype. Leukemia, 26, 17611770.
  • Stühmer, T., Arts, J., Chatterjee, M., Borawski, J., Wolff, A., King, P., Einsele, H., Leo, E. & Bargou, R.C. (2010) Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585. British Journal of Haematology, 149, 529536.
  • Tan, J., Li, Z., Lee, P.L., Guan, P., Aau, M.Y., Lee, S.T., Feng, M., Lim, C.Z., Lee, E.Y., Wee, Z.N., Lim, Y.C., Karuturi, R.K. & Yu, Q. (2013) PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy. Cancer Discov, 3, 11561171.
  • Usmani, S.Z., Crowley, J., Hoering, A., Mitchell, A., Waheed, S., Nair, B., AlSayed, Y., Vanrhee, F. & Barlogie, B. (2013) Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? Leukemia, 27, 226232.
  • Vadas, O., Burke, J.E., Zhang, X., Berndt, A. & Williams, R.L. (2011) Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. Sci Signal, 4, re2.
  • Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M. & Bilanges, B. (2010) The emerging mechanisms of isoform-specific PI3K signalling. Nature Reviews Molecular Cell Biology, 11, 329341.
  • Vanhaesebroeck, B., Stephens, L. & Hawkins, P. (2012) PI3K signalling: the path to discovery and understanding. Nature Reviews Molecular Cell Biology, 13, 195203.
  • Vivanco, I. & Sawyers, C.L. (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nature Reviews Cancer, 2, 489501.
  • Wetzker, R. & Rommel, C. (2004) Phosphoinositide 3-kinases as targets for therapeutic intervention. Current Pharmaceutical Design, 10, 19151922.
  • Zöllinger, A., Stühmer, T., Chatterjee, M., Gattenlöhner, S., Haralambieva, E., Müller-Hermelink, H.K., Andrulis, M., Greiner, A., Wesemeier, C., Rath, J.C., Einsele, H. & Bargou, R.C. (2008) Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma. Blood, 112, 34033411.